Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas furthers oncology ambitions with $765 million Medivation deal

This article was originally published in Scrip

Executive Summary

Astellas has acquired global rights to Medivation's investigational prostate cancer drug MDV3100, in an alliance worth up to $765 million in up-front and milestone payments to the US firm.

You may also be interested in...



Takeda Culls Shunned Ex-Shire Asset After EC Lifts Antimonopoly Concerns

Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

Post-IPO Zentalis Plows New Ground With China Oncology Venture

US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel